Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI-net).
Cabotegravir
HIV
Rilpivirine
Virologic suppression
capacity
discontinuation
effectiveness
long‐acting injectable
real‐world evidence
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
10 Jun 2024
10 Jun 2024
Historique:
received:
21
03
2024
accepted:
17
05
2024
medline:
11
6
2024
pubmed:
11
6
2024
entrez:
10
6
2024
Statut:
aheadofprint
Résumé
Long-acting injectable cabotegravir + rilpivirine (CAB + RPV LAI) was approved for use in virally suppressed adults in the England and Wales national health service in November 2021. We describe a service evaluation of delivery processes and outcomes in 12 clinics. Centres populated a database using information from local policies and clinical records. Services were asked to describe approval processes, clinic pathways, and adherence to national guidelines. Additional data were collected on reasons for regimen choice, treatment discontinuations, and management of viraemia. In total, 518 adults from 12 clinics were approved for CAB + RPV LAI between February 2022 and December 2023. Of the 518 people approved for CAB + RPV LAI, 423 received at least one injection. Median duration on CAB + RPV was 7.5 months (interquartile range 3.7-11.3). In total, 97% of injections were administered within the ±7-day window. Virological failure occurred in 0.7%, and 6% discontinued CAB + RPV. In this large UK-based cohort, robust approval processes and clinic protocols facilitated on-time injections and low rates of both discontinuation and virological failure.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.
Références
Medicines and Healthcare products Regulatory Agency. Vocabria Summary of Product Characteristics. https://products.mhra.gov.uk/product/?product=VOCABRIA%20400%20MG%20PROLONGED-RELEASE%20SUSPENSION%20FOR%20INJECTION
Orkin C, Arasteh K, Górgolas Hernández‐Mora M, et al. Long‐acting Cabotegravir and Rilpivirine after Oral induction for HIV‐1 infection. N Engl J Med. 2020;382(12):1124‐1135. doi:10.1056/NEJMoa1909512
Orkin C, Oka S, Philibert P, et al. Long‐acting cabotegravir plus rilpivirine for treatment in adults with HIV‐1 infection: 96‐week results of the randomised, open‐label, phase 3 FLAIR study. Lancet HIV. 2021;8(4):e185‐e196. https://linkinghub.elsevier.com/retrieve/pii/S2352301820303404
Orkin C, Bernal Morell E, Tan DHS, et al. Initiation of long‐acting cabotegravir plus rilpivirine as direct‐to‐injection or with an oral lead‐in in adults with HIV‐1 infection: week 124 results of the open‐label phase 3 FLAIR study. Lancet HIV. 2021;8(11):e668‐e678. https://linkinghub.elsevier.com/retrieve/pii/S2352301821001843
Swindells S, Lutz T, Van Zyl L, et al. Week 96 extension results of a phase 3 study evaluating long‐acting cabotegravir with rilpivirine for HIV‐1 treatment. Aids. 2022;36(2):185‐194. doi:10.1097/QAD.0000000000003025
Swindells S, Andrade‐Villanueva JF, Richmond GJ, et al. Long‐acting Cabotegravir and Rilpivirine for maintenance of HIV‐1 suppression. N Engl J Med. 2020;382(12):1112‐1123. doi:10.1056/NEJMoa1904398
Overton ET, Richmond G, Rizzardini G, et al. Long‐acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV‐1 infection (ATLAS‐2M), 48‐week results: a randomised, multicentre, open‐label, phase 3b, non‐inferiority study. Lancet. 2020;396(10267):1994‐2005. https://linkinghub.elsevier.com/retrieve/pii/S0140673620326660
Jaeger H, Overton ET, Richmond G, et al. Long‐acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV‐1 infection (ATLAS‐2M), 96‐week results: a randomised, multicentre, open‐label, phase 3b, non‐inferiority study. Lancet HIV. 2021;8(11):e679‐e689. https://linkinghub.elsevier.com/retrieve/pii/S2352301821001855
National Institute for Health and Care Excellence. Single Technology Appraisal: Cabotegravir and rilpivirine for treating HIV‐1 [ID3766] [Internet]. 2021 https://www.nice.org.uk/guidance/ta757/documents/committee-papers
Ramgopal MN, Castagna A, Cazanave C, et al. Efficacy, safety, and tolerability of switching to long‐acting cabotegravir plus rilpivirine versus continuing fixed‐dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12‐month results (SOLAR): a randomised, open‐label, phase 3b, non‐inferiority trial. Lancet HIV. 2023;10(9):e566‐e577. https://linkinghub.elsevier.com/retrieve/pii/S2352301823001364
Van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to Dolutegravir/lamivudine fixed‐dose 2‐drug regimen vs continuing a Tenofovir Alafenamide–based 3‐ or 4‐drug regimen for maintenance of Virologic Suppressibhivaon in adults living with human immunodeficiency virus type 1: phase 3, randomized, Noninferiority TANGO Study. Clin Infect Dis. 2020;71(8):1920‐1929. https://academic.oup.com/cid/article/71/8/1920/5697294
Acosta RK, Willkom M, Andreatta K, et al. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil fumarate (TDF) in the presence of pre‐existing NRTI resistance. J Acqu Immune Deficiency Synd. 2020;85(3):363‐371. doi:10.1097/QAI.0000000000002454
Borch J, Sherzer J, Jonsson‐Oldenbuttel C, et al. Six‐month outcomes of every 2‐months long‐acting cabotegravir and rilpivirine in a real‐world setting: effectiveness, adherence to injections and patient‐reported outcomes from PLWHIV in the German CARLOS cohort. International Congress on Drug Therapy in HIV Infection, Glasgow, UK. 2022 https://medinfo.gsk.com/5f95dbd7‐245e‐4e65‐9f36‐1a99e28e5bba/8c8a4e0e‐d003‐415a‐9516‐d9dff4c9bbcd/8c8a4e0e‐d003‐415a‐9516‐d9dff4c9bbcd_viewable_rendition__v.pdf?medcommid=REF‐‐ALL‐004533
Orkin C, Schapiro JM, Perno CF, et al. Expanded multivariable models to assist patient selection for long‐acting Cabotegravir + Rilpivirine treatment: clinical utility of a combination of patient, drug concentration, and viral factors associated with virologic failure. Clin Infect Dis. 2023;77(10):1423‐1431. https://academic.oup.com/cid/article/77/10/1423/7204256
European Medicines Agency. Vocabria summary of product characteristics. [cited 2024 Feb 26]. Available from: https://www.ema.europa.eu/en/documents/product‐information/vocabria‐epar‐product‐information_en.pdf
Waters L, Winston A, Reeves I. BHIVA guidelines on antiretroviral treatment for adults living with HIV‐1. HIV Med. 2022;23(suppl 5):3‐115. https://www.bhiva.org/file/63513a1745ea9/BHIVA‐guidelines‐on‐antiretroviral‐treatment‐for‐adults‐living‐with‐HIV‐1‐2022.pdf
Brain J, Schofield J, Gerrish K, et al. A Guide for Clinical Audit, Research and Service Review. Healthcare Quality Improvement Partnership; 2011.
Orkin C, Apea V. International Women's day—how can I help? The Lancet HIV. 2022;9(4):e228‐e229. https://linkinghub.elsevier.com/retrieve/pii/S2352301822000601
Elias A, Ring K, Apea V, Orkin C. Inclusion of women, black and people of colour (BPoC) and older adults in real‐world and implementation studies evaluating long‐acting injectable (LA‐I) Cabotegravir (CAB) and Rilpivirine (RPV): a rapid review. Poster Presented at: 19th European AIDS Conference; Warsaw, Poland 2023. doi:10.1111/hiv.13572
UK Health Security Agency [Internet]. HIV: annual data tables. 2023 https://www.gov.uk/government/statistics/hiv-annual-data-tables
Farooq HZ, Apea V, Kasadha B, et al. Study protocol: the ILANA study‐exploring optimal implementation strategies for long‐acting antiretroviral therapy to ensure equity in clinical care and policy for women, racially minoritised people and older people living with HIV in the UK ‐ a qualitative multiphase longitudinal study design. BMJ Open. 2023;13(7):e070666.
Orkin C, Haviland J, Wong YL, et al. Implementing LA Cabotegravir (CAB) + Rilpivirine (RPV) therapy in six UKUK clinics & in the community‐ILANA. Poster Ppresented at: Conference on Retroviruses and Opportunistic Infections (CROI). Denver, Colorado 2024.
Sension M, Hsu RK, Fusco JS, et al. Real‐world effectiveness of long‐acting Cabotegravir + Rilpivirine in Virologically suppressed treatment‐experienced individuals: two years of data from the OPERA® cohort. Open Forum Infectious Diseases. 2023;10(suppl 2):ofad500. doi:10.1093/ofid/ofad500.1443/7446883
Deschanvres C, Allavena C, Palich R, et al. Cabotegravir‐Rilpivirine lLong acting: dData in real life setting in a French Cohort, in. 19th European AIDS Conference, Warsaw, Poland. 2023 https://www.natap.org/2023/EACS/EACS_59.htm
Jongen V, Wit F, van Eeden A. Effectiveness of injectable long‐acting cabotegravir and rilpivirine for the treatment of HIV‐1: results from the Dutch ATHENA national observational cohort.’, in. 19th European AIDS Conference, Warsaw, Poland. 2023 https://www.natap.org/2023/EACS/EACS_69.htm.